Country for PR: United States
Contributor: PR Newswire New York
Saturday, March 09 2019 - 08:34
Satipharm Supports HCP Education for Medicinal Cannabis
VANCOUVER, BC., Mar. 9, 2019 /PRNewswire-AsiaNet/--

Satipharm Limited, a subsidiary of Harvest One Cannabis Inc. (TSXV: HVT) 
("Satipharm" or "the Company") has today announced it will sponsor a series of 
educational seminars, run by Medical Cannabis Research Australia (MCRA), to be 
held throughout the country in March.  These seminars are an important source 
of clinical information for healthcare professionals and the talks will be by 
prescribers, pharmacists, patient advocates and other healthcare professionals.

Logo - 

Medicinal Cannabis was legalised in Australia in November 2016. The global 
legal cannabis market is expected to grow to over US$20 billion by 2020. There 
is good clinically-trialled evidence that cannabis-based medicines may be of 
benefit in chronic pain, multiple sclerosis, chemotherapy-induced nausea and 
vomiting as well as treatment-resistant epilepsy. 

Jonathan Hartshorn, CEO Satipharm commented,

    "We are proud to support an organisation that is dedicated to the education 
of healthcare professionals on the use of medicinal cannabis. We know from the 
families in Australia that use our CBD Gelpell(R) capsules, that   cannabinoids 
have the power to dramatically transform the quality of life  in many patients 
who have no other therapeutic options. We hope that the education provided by 
this event will see more people's lives transformed using medicinal cannabis." 

This event continues Satipharm's commitment to support research and education 
around medicinal cannabis. In July 2018, Satipharm completed a phase 2 clinical 
study to test Satipharm's proprietary 50mg CBD Gelpell(R) capsules in 
paediatric patients with very severe, uncontrolled, treatment-resistant 
epilepsy (TRE). 

In this pilot study, Satipharm CBD 50mg Gelpell(R) capsules were safe for use 
and demonstrated a potent seizure-reducing effect among paediatric TRE 
patients. This result was achieved with Satipharm CBD 50mg Gelpell(R) capsules 
that do not contain the psychoactive cannabinoid THC.  

Accessing Satipharm 50mg CBD Gelpell(R) Capsules

Satipharm 50mg CBD Gelpell(R) capsules are available in Australia through the 
Therapeutic Goods Administration (TGA) Special Access Scheme (Category B) or 
through the Authorised Prescriber Scheme. Patients wishing to access medicinal 
cannabis products should discuss access with their physician and make 
themselves familiar with the processes by reading the TGA advice at 

Once the physician has the required approval, this prescription can then be 
sent to our distributor, HL Pharma, who will arrange delivery to a dispensing 
pharmacy. HL Pharma can be contacted at 

About Satipharm

Satipharm is a health and wellbeing company which is specialised in the 
development and manufacture of cannabinoid-based products from the cannabis 
plant. Satipharm's focus is on delivering the highest quality products that are 
designed specifically with the needs of our customers in mind. Satipharm 
provides products of exceptional, consistent quality, that are manufactured in 
a regulated, safe environment in line with Good Manufacturing Practice (GMP).

About MCRA

The MCRA's mission is to help bring Medical Cannabis to those who need it by 
helping fund those researching the possibilities, educating those who can 
prescribe it and advocating to those who can make it available to everyone on 
behalf of patients everywhere. They are a Not-for-Profit Registered Australian 
Charity seeking to improve the quality of life of patients for whom 
conventional medicines have failed. Educate. Advocate. Research.

SOURCE:  Satipharm Limited

CONTACT: Satipharm Enquiries: Catherine Harvey, Operations Director,  OR 
         Media Enquiries: